Sustained adaptive immunity to pathogens provides effective protection against 
cells re-encounter a cognate antigen, they mount a robust and rapid response to control the infection at early stage. 4 In the case of a M.tb infection, there are more CD4 + T cells than CD8 + T cells at the sites of infection, and the CD4 + T cells have been shown to play multiple roles in initiating and propagating the T-cell responses in animal models and human cases. 5, 6 CD4 + T cells with effector or effector-memory phenotype played a major role in controlling the mycobacteria at site of infection and limited progression of the disease. 7 Some of them had a phenotype of CD44 + CD62L low , 8 and produced Th1-type cytokines, such as IFN-γ, TNF-α, and IL-2. These effector cytokines eliminated the infected cells and controlled M.tb replication. 9, 10 Thus, many vaccine developments have been focused on identifying new CD4 + T-cell epitopes inducing Th1-type responses, or modifying BCG to improve efficacy for providing a broader protection. 11, 12 Among them,
ESAT-6 and CFP-10, which induce dominant Th1-type CD4 + T-cell responses, have been evaluated and shown potentially protective effects. The ESAT-6, formatted as an ESAT-6-Ag85 fusion protein, promoted strong and long-lived M.tb-specific T-cell responses in naïve human volunteers 13, 14 ; the CFP-10, previously used for disease diagnosis, could induce IFN-γ release and reduce IL-4 secretion of CD4 + T cells, as well as promote antibody response with an enhanced IgG2a/ IgG1 ratio in mice. 15 Although the evaluation is ongoing, establishment of adaptive Th1-type CD4 + T-cell response with effector or effectormemory phenotype is one of the targets for vaccine development to prevent TB.
Induction of only Th1-type memory responses did not sufficiently eliminate M.tb, nor did it efficiently protect the host; the location of vaccine-primed memory cells also had an impact on the efficiency of protection. 16, 17 Limited success of TB vaccine trials might simply be due to failure to elicit, maintain, and/or deliver sufficient effector-functional T cells to the respiratory tract. 18, 19 A population of T cells that reside in peripheral tissues has been recently identified as tissue-resident memory T cells (T RM ) . 20, 21 They are at the frontline, encountering pathogen invasions, and are antigenexperienced memory cells. They can expand rapidly in response to cognate antigens to establish a barrier that limits the infection of target cells without the time-consuming procedure of recruiting effector cells from lymphoid tissues and the circulation. 22 Intranasal immunization induces not only systemic but also airway mucosal immune responses, while subcutaneous immunization preferably elicits responses in the serum and peripheral lymphoid tissues. 23 Intranasal immunization with BCG preferably induced TB-specific CD4 + T cells in the lung tissue, 7 and lung tissue CD4 + memory T cellsmediated adaptive immunity against Bordetella pertussis and Coronavirus infections efficiently. [24] [25] [26] The route of immunization has an impact on the location and differentiation of vaccination-primed cells, and intranasal immunization has being tested as a promising approach to induce mucosal immunity in the respiratory tract for prevention of M.tb, influenza virus, respiratory syncytial virus, and other pathogenic infections. 11, 13, [26] [27] [28] The escalating magnitude of T-cell response and IFN-γ production induced by BCG did not provide additional protection against M.tb infection. 18 In search for new TB vaccine candidates, we evaluated Rv3615c, a protein whose secretion is dependent on a component of RD1, for potency of inducing T-cell responses of patients with tuberculosis pleurisy. 9 Rv3615c has previously been identified as an ESX-1 substrate protein C (EspC) and has been known as a protein with similar amino acid length and homologous sequence as ESAT-6, CFP-10, and other members of the ESAT-6 family. 29, 30 The encoding region for Rv3615c is out of RD1 but its secretion is controlled by the ESAT-6 secretion system. 31 Although not expressed in BCG, Rv3615c
is actively expressed and accessible to the antigen-presenting process during intracellular M.tb infections in vivo. 32, 33 In a mouse model, subcutaneous immunization with recombinant protein containing Rv3615c promoted Th1-type cytokine productions in the spleen, and both CD4 + and CD8 + T cells were responsible for the elevated cytokine productions, and a portion of them coexpressed multiple cytokines. 34 In human cases, Rv3615c or its overlapping peptides elicited
PBMCs isolated from patients with active TB or latent TB infection (LTBI) to produce IFN-γ, with a portion of them coproducing IL-2. 
| MATERIALS AND METHODS

| Animals
Female C57BL/6 mice aged 6-8 weeks were purchased from the Laboratory Animal Center of Sun Yat-Sen University (S.C. XK 2016-0029) and maintained under pathogen-free conditions. Mice were age-and weight-matched in each experiment. All animal studies were approved by the Zhongshan School of Experimental Animal Ethics
Committee, Sun Yat-Sen University, Guangzhou, China.
| Antigen, adjuvant, and immunizations
The twice into the lower quadrant of the abdomen (200 μL/mouse). For intranasal immunization, the mixture was suspended in PBS and injected intranasally through the nasal cavity while the mice were anaesthetized with bromethane (20 μL/mouse). A detail schedule of prime and boost is shown in Figure 1 .
| In vivo labelling of cells in circulation
To distinguish cells in lung parenchyma (LP) from lung vasculature (LV),
we used a protocol previously reported to label cells in circulation in vivo. 37 In short, anti-CD45-phycoerythrin (clone 30-F11, BD Bioscience) was diluted to 10 μg/mL in sterile PBS and injected into mice via the tail vein in a volume of 300 μL/mouse. The mice were killed 5 min later, and mononuclear cells were isolated from tissues for experiments. Cells labelled with anti-CD45 were identified as in LV, and its counterpart was identified as in LP in flow cytometry data analysis.
| Sample collection and cell preparation
Blood was obtained through retro-orbital bleeding, and the serum was prepared following a standard procedure. Lung tissues were mechanically dissociated into 1-2 mm 3 pieces, then transferred to a culture dish containing 2 mL RPMI 1640, 5% fetal calf serum (FCS), 2 mg/mL collagenase IV, and 10 mg/mL DNase I (Sigma-Aldrich, St.
Louis, MO, USA), and incubated for 1 hour at 37°C in a shaker. Cells in the BALF were collected by centrifugation. 
| ELISA and ELISPOT assay
| Flow cytometry analysis
Detection of cell phenotype and intracellular cytokine expressions using flow cytometry has been previously described. 9 In short, for /mL) were stimulated with or without protein or peptides (10 μg/mL) plus anti-CD28
(1 μg/mL) for 12 hours at 37°C and 5% CO 2 . Brefeldin A (10 μg/mL, Sigma-Aldrich) was added into the culture during the final 6 hours.
The cells were washed twice with PBS containing 0.1% BSA and 0.05% sodium azide. After staining for phenotyping as described 
| Antibody detection
Detection of antigen-specific antibodies in BALF and serum by ELISA has been previously described. 38 In short, microtitre plates were respectively. The plates were washed with 0.05% Tween 20/PBS and developed using TMB substrate. The reaction was stopped with 2N H 2 SO 4 , and data were collected by an ELISA reader. The endpoint titre was defined as the highest dilution that gave an absorbance value above the optical density of 0.1 and was analysed using GraphPad Prism 5 (GraphPad Software Inc., San Diego, CA, USA).
| Statistical analysis
All statistical analysis was performed with GraphPad Prism 5 (GraphPad Software Inc.) by either unpaired Student's t test when comparing two groups, one-way ANOVA for more than two groups, or two-way ANOVA for two variables. Data were presented as mean or mean ± SD. ***P < 0.001, **P < 0.01, *P < 0.05. 
| RESULTS
|
| Intranasal immunization induced effector-memory CD4 + T cells with multicytokine coexpressions in lung
We studied the differentiation of CD4 + T cells following I.N. or S.C. immunization with Rv3615c+CpG. Data showed that I.N. 
| DISCUSSION
Establishment of a long-term immune memory to a specific pathogen is essential for the success of a vaccination. 38 In our previous study, could be an effective way to induce adaptive immunity in the airway and the lungs.
In our prime and boost procedure, adjuvant CpG promoted immunogenicity of Rv3615c. The use of CpG was based on our experience and previous studies. 49 The adjuvant might activate the innate immune system, lower the threshold for signalling of activation, and reduce the quantity of antigen required for initiating an immune response. 36 We have not, here, tried to figure out the mechanism of T-cell response against a broad spectrum of targets, and with diverse functionalities, provides a better protection compared to a narrow response. Our study provides important information related to inducing broad spectrum and quality immunity against M.tb infections, and sheds light on the rational design of vaccines.
